# Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

> **NCT01046630** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 128 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** AZD6765
- **DRUG:** Ketamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01046630
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2014-10-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01046630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01046630, "Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01046630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*